| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| IL-7 | HOT GMP-L07H15 | GMP Human IL-7 Protein (E. coli) | Human | E. coli | ![]() | MSSDS-PAGE | $1130.00 50ug | ||
| IL-7 | HOTDMF GMP-L07H15GB01 | CytoPak GMP Human IL-7 Protein (E. coli) | Human | E. coli | ![]() | MSSDS-PAGE | $390.00 10ug | ||
| IL-7 | HOTDMF GMP-L07H15GB02 | CytoPak GMP Human IL-7 Protein (E. coli) | Human | E. coli | ![]() | MSSDS-PAGE | Inquiry 50ug | ||
| IL-7 | HOTDMF GMP-L07H24GB01 | CytoPak GMP Human IL-7 Protein | Human | HEK293 | ![]() | SDS-PAGE | Inquiry 10ug | ||
| IL-7 | HOTDMF GMP-L07H24 | GMP Human IL-7 Protein | Human | HEK293 | ![]() | SDS-PAGE | $1130.00 50ug | ||
| IL-7 | HOT IL7-H4219 | Human IL-7 Protein, premium grade | Human | HEK293 | ![]() | SDS-PAGE | $260.00 20ug | ||
| IL-7 | HOT IL7-H5253 | Human IL-7 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $410.00 50ug | ||
| IL-7 | Cynomolgus IL-7 Protein, His Tag (HPLC verified) | Cynomolgus | HEK293 | ![]() | HPLCSDS-PAGE | $410.00 50ug | |||
| IL-7 | Human IL-7 Protein (E. coli), premium grade | Human | E. coli | ![]() | SDS-PAGE | $260.00 20ug | |||
| IL-7 | Human IL-7 Protein (E. coli), Research Grade | Human | E. coli | ![]() | SDS-PAGE | $189.00 20ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Anti-GPC3 chimeric antigen receptor T cell therapy (Hunan Zhaotai Yongren Biotech/Guangdong Zhaotai Invivo Biomedicine) | Phase 1 Clinical | Guangdong Zhaotai Invivo Biomedicine Co Ltd, Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details | |
| HCW-9206 | HCW-9206 | Phase 1 Clinical | HCW Biologics Inc | Leukemia, Myeloid, Acute; Solid tumours | Details |
| ADP-TILIL7 | ADP-TILIL7 | Phase 1 Clinical | Adaptimmune Therapeutics Plc | Melanoma | Details |
| GSK-3888130-B | GSK3888130B; GSK-3888130; GSK-3888130-B | Phase 1 Clinical | Glaxosmithkline Plc | Colitis, Ulcerative; Multiple Sclerosis | Details |
| BNT-152 | BNT-152 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
